As expected, apigenin treatment reduced the expression of AhR in EDC‐augmented eosinophilic asthma mice and significantly decreased airway inflammation, type 2 cytokines, and airway hyperresponsiveness compared to mice that were not treated with apigenin. This evidence concerns the gene AHR and airway hyperresponsiveness.